XML 33 R14.htm IDEA: XBRL DOCUMENT
v3.25.1

Intangible Assets and Goodwill | 3 Months Ended
--- | ---
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets and Goodwill |
Note 7: | Intangible Assets and Goodwill
Intangible Assets Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:
|  |  |  | As of March 31, 2025 |  | As of December 31, 2024
(In millions) |  | Estimated Life |  | Cost |  | Accumulated Amortization |  | Net |  | Cost |  | Accumulated Amortization |  | Net
Completed technology |  | 2-31 years |  | $ | 14,103.6 |  |  | $ | (6,325.9) |  |  | $ | 7,777.7 |  |  | $ | 14,138.4 |  |  | $ | (6,254.1) |  |  | $ | 7,884.3 |
In-process research and development |  | Indefinite until commercialization |  | 1,642.9 |  |  | — |  |  | 1,642.9 |  |  | 1,642.9 |  |  | — |  |  | 1,642.9 |
Priority review voucher |  | Indefinite |  | 100.0 |  |  | — |  |  | 100.0 |  |  | 100.0 |  |  | — |  |  | 100.0 |
Trademarks and trade names |  | Indefinite |  | 64.0 |  |  | — |  |  | 64.0 |  |  | 64.0 |  |  | — |  |  | 64.0 |
Total intangible assets |  |  |  | $ | 15,910.5 |  |  | $ | (6,325.9) |  |  | $ | 9,584.6 |  |  | $ | 15,945.3 |  |  | $ | (6,254.1) |  |  | $ | 9,691.2 |
Amortization and Impairments For the three months ended March 31, 2025, amortization and impairment of acquired intangible assets, totaled $111.8 million, compared to $78.3 million in the prior year comparative period. Th e increase wa s primarily due to amortization for the acquired intangible assets associated with SKYCLARYS and TYSABRI. For the three months ended March 31, 2025 and 2024, we had no im pair ment charges. Completed Technology Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between 2 to 31 years, with a remaining weighted average useful life of 12 years. IPR&D Related to Business Combinations IPR&D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&D balances are adjustments related to foreign currency exchange rate fluctuations. The carrying value associated with our IPR&D assets as of March 31, 2025 and December 31, 2024, primarily relates to the IPR&D programs we acquired in connection with our acquisition of HI-Bio in July 2024, with an estimated fair value of approximately $1.6 billion. Priority Review Voucher In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease PRV which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the PRV based on its estimated fair value of $100.0 million as an intangible asset. The estimated fair value of the PRV was based on external purchase and sale transactions of similar vouchers at the time of acquisition. For additional information on our acquisitions of Reata and HI-Bio, please read Note 2, Acquisitions, to our consolidated financial statements included in our 2024 Form 10-K. Estimated Future Amortization of Intangible Assets The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:
(In millions) |  | As of March 31, 2025
2025 (remaining nine months) |  | $ | 350.0 |
2026 |  | 560.0 |
2027 |  | 600.0 |
2028 |  | 630.0 |
2029 |  | 665.0 |
2030 |  | 700.0 |
Goodwill The following table provides a roll forward of the changes in our goodwill balance:
(In millions) |  | As of March 31, 2025
Goodwill, December 31, 2024 |  | $ | 6,478.9 |
Goodwill resulting from HI-Bio acquisition(1) |  | (5.1) |
Other |  | 3.3 |
Goodwill, March 31, 2025 |  | $ | 6,477.1 |
(1) Goodwill resulting from HI-Bio acquisition for the three months ended March 31, 2025, relates to HI-Bio measurement period adjustments recognized during the first quarter of 2025 related to certain income tax adjustments. For additional information on our acquisition of HI-Bio, please read Note 2, Acquisitions, to these condensed consolidated financial statements. As of March 31, 2025, we had no ac cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration